Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: A comment on the results presented in JVH Special Issue

Journal of Viral Hepatitis

Volumn 21, Issue 12, 2014, Pages e167-e168

  Hickman, M ^a   Martin, N ^a   Vickerman, P ^a   Hutchinson, S ^b,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DISEASE COURSE; DISEASE TRANSMISSION; END STAGE LIVER DISEASE; HEALTH BEHAVIOR; HEPATITIS C; HUMAN; LETTER; LIVER CANCER; RISK ASSESSMENT; FEMALE; HEPATITIS C, CHRONIC; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE;

EID: 84910674852     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12340     Document Type: Letter

References (11)

1. Murray CJ, Vos T, Lozano R, et al,. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223.
2. Nelson PK, Mathers BM, Cowie B, et al,. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
3. Bruggmann P, Berg T, Ovrehus AL, et al,. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (Suppl. 1): 5-33.
4. Razavi H, Waked I, Sarrazin C, et al,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 1): 34-59.
5. Wedemeyer H, Duberg AS, Buti M, et al,. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (Suppl. 1): 60-89.
6. Harris RJ, Thomas B, Griffiths J, et al,. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol 2014; 61: 530-537.
7. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD,. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
8. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M,. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-1144.
9. Martin NK, Vickerman P, Grebely J, et al,. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598-609.
10. Hethcote HW, Yorke J,. Gonorrhoea Transmission Dynamics and Control. New York: Springer-Verlag, 1974.
11. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P,. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57 (Suppl. 2): S39-S45.